Resistance to the antibiotic vancomycin in enterococci, a class of bacteria, has spread rapidly in the past ten years-causing a large number of hospital-acquired infections. Vancomycin is one of the last antibiotics that can be used to treat infections caused by multiple-resistant staphylococcus aureus and other harmful bacteria. In two symposia, cosponsored by the ACS divisions of organic chemistry and medicinal chemistry, leading researchers will examine the structure of vancomycin--and look at how and where antibiotic-resistant strains develop, and how to prevent their spread.
What: Symposia entitled "Antibiotic Resistance: Vancomycin and Beyond"
Where: American Chemical Society 218th National Meeting
When: Wednesday, August 24, 1999
Organic Chemistry Division:
8:15 a.m. to 12:05 p.m.,
Convention Center, La Nouvelle Ballroom A/B
Medicinal Chemistry Division:
1:00 p.m. to 4:15 p.m.,
Convention Center, Room R07-R08
Presenters:
Dale L. Boger, The Scripps Research Institute, La Jolla.
David A. Evans, Harvard University, Cambridge
K. C. Nicolaou, The Scripps Research Institute and the University of California, San Diego
Dudley H. Williams, University of Cambridge,Cambridge, U. K.
Christopher T. Walsh, Ph.D., Harvard Medical School, Boston
Gerard D. Wright, Ph.D., McMaster University, Hamilton, Ont.
Richard C. Thompson, Ph.D., Lilly Research Laboratories,Indianapolis, Ind.
Daniel E. Kahne, Ph.D., Princeton University
A nonprofit organization with a membership of nearly 159,000 chemists and chemical engineers, the American Chemical Society publishes scientific journals and databases, convenes major research conferences, and provides educational, science policy and career programs in chemistry. Its main offices are in Washington, D.C., and Columbus, Ohio. ( http://www.acs.org )